Minimal Residual Disease Testing Market Growth Outlook Through 2024-2033

Overview and Scope
Minimal residual disease testing refers to a very sensitive test to detect cancer cells in the patient’s body that may remain after treatment. It is used to monitor the effectiveness of cancer treatment and inform future treatment strategies.

Sizing and Forecast
The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.41 billion in 2023 to $1.61 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to advancements in cancer research, treatment monitoring needs, clinical evidence, regulatory support, patient outcome improvement..

The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing cancer incidence, therapeutic advancements, precision medicine trends, shift toward early detection, healthcare system integration.. Major trends in the forecast period include integration of liquid biopsy approaches, focus on early detection of relapse, expansion of mrd testing in clinical trials, increasing adoption in pediatric oncology, collaborations for research and development..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-testing-global-market-report

Segmentation & Regional Insights
The minimal residual disease testing market covered in this report is segmented –

1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, Other End Users

North America was the largest region in the minimal residual disease testing market in 2023. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=9970&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease testing market going forward. Cancer refers to a condition when a few of the body’s cells grow out of control and spread to other bodily regions. Cancer stages are primarily detected through minimal residual disease testing, which is a very sensitive method to detect cancer cells in the human body. It helps cancer patients prevent the disease at an early stage, boosting the minimal residual disease testing market. For instance, in 2022, according to the reports shared by the American Cancer Society Inc., a US-based nonprofit organization, approximately 1.9 million fresh instances of cancer are projected to be diagnosed, leading to an estimated 609,360 cancer-related fatalities in the United States in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease testing market.

Key Industry Players

Major companies operating in the minimal residual disease testing market report are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A. .

The minimal residual disease testing market report table of contents includes:

1. Executive Summary

2. Minimal Residual Disease Testing Market Characteristics

3. Minimal Residual Disease Testing Market Trends And Strategies

4. Minimal Residual Disease Testing Market – Macro Economic Scenario

5. Global Minimal Residual Disease Testing Market Size and Growth
.
.
.

31. Global Minimal Residual Disease Testing Market Competitive Benchmarking

32. Global Minimal Residual Disease Testing Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Testing Market

34. Minimal Residual Disease Testing Market Future Outlook and Potential Analysis

35. Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model